Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016;31(sup2):148-161.
doi: 10.1080/14756366.2016.1193734. Epub 2016 Jul 17.

Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases

Affiliations
Comparative Study

Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases

Robert S Foti et al. J Enzyme Inhib Med Chem. 2016.

Abstract

The CYP26s are responsible for metabolizing retinoic acid and play an important role in maintaining homeostatic levels of retinoic acid. Given the ability of CYP2C8 to metabolize retinoic acid, we evaluated the potential for CYP2C8 inhibitors to also inhibit CYP26. In vitro assays were used to evaluate the inhibition potencies of CYP2C8 inhibitors against CYP26A1 and CYP26B1. Using tazarotenic acid as a substrate for CYP26, IC50 values for 17 inhibitors of CYP2C8 were determined for CYP26A1 and CYP26B1, ranging from ∼20 nM to 100 μM, with a positive correlation observed between IC50s for CYP2C8 and CYP26A1. An evaluation of IC50's versus in vivo Cmax values suggests that inhibitors such as clotrimazole or fluconazole may interact with CYP26 at clinically relevant concentrations and may alter levels of retinoic acid. These findings provide insight into drug interactions resulting in elevated retinoic acid concentrations and expand upon the pharmacophore of CYP26 inhibition.

Keywords: CYP26; CYP2C8; homology model; retinoic acid; tazarotenic acid.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CYP26-catalyzed metabolism of tazarotenic acid to tazarotenic acid sulfoxide.
Figure 2.
Figure 2.
Structures of key compounds used to compare inhibition of tazarotenic acid sulfoxidation to retinoic acid 4-hydroxylation as noted in Table 1 or in docking simulations.
Figure 3.
Figure 3.
Correlation between previously reported CYP26 IC50 values using 9-cis-retinoic acid as a probe substrate and IC50 values generated using tazarotenic acid as a probe substrate for CYP26A1 (r2 = 0.78) or CYP26B1 (r2 = 0.62) in vitro activity in recombinant CYP enzymes. Lines represent unity, 3-fold and10-fold difference.
Figure 4.
Figure 4.
Single concentration (10 μM) inhibition screen using tazarotenic acid as a probe substrate of CYP26 activity. Inhibition values ranged from no inhibition to greater than 90% inhibition.
Figure 5.
Figure 5.
In vitro IC50 curves for select CYP26A1 or CYP26B1 inhibitors using tazarotenic acid as a probe substrate. Data points represent the average of incubations conducted in triplicate and IC50 values were calculated using a three-parameter inhibition model with the Hill slope fixed to 1.
Figure 6.
Figure 6.
Correlation between previously reported CYP2C8 IC50 values and CYP26A1 (r2 = 0.849) or CYP26B1 (r2 = 0.258) IC50 values generated using tazarotenic acid as a probe substrate. Lines represent unity, 3-fold and10-fold difference.
Figure 7.
Figure 7.
Computational docking of clotrimazole (A, CYP26A1; B, CYP26B1), zafirlukast (C, CYP26A1) and candesartan cilexetil (D, CYP26B1) into the active sites of CYP26. The docking orientation of clotrimazole in the active sites of CYP26A1 and CYP26B1 suggests the potential for the imidazole moiety to inhibit the enzyme through type II binding interactions. Active site residues involved in the binding of zafirlukast in the active site of CYP26A1 (R90, W112, F222, and F299) and candesartan cilexetil in the active site of CYP26B1 (W117, F295, F299 and Y372) are similar to the active site residues known to be involved in retinoic acid binding for each isoform. Portions of the protein structure are not displayed for added clarity.
Figure 8.
Figure 8.
Spectral binding results for clotrimazole with recombinantly expressed CYP26A1, CYP26B1 or CYP2C8, suggesting enzyme inhibition occurs through type II binding interactions with the heme. Ks,unb affinity constants for CYP26A1 (13.3 nM), CYP26B1 (24.7 nM) and CYP2C8 (75.5 nM) were determined through nonlinear regression analysis (inset figures) and corrected for nonspecific binding in the in vitro assays.
Figure 9.
Figure 9.
Computational docking of ketoconazole (A, CYP26A1; B, CYP26B1) or R115866 (A, CYP26A1 or B, CYP26B1) supports the reported type II binding interactions observed for CYP26A1 and suggests a similar binding interaction will occur with CYP26B1. The sp2 hybridized nitrogen was located within 3 Å of the heme iron in all cases. Portions of the protein structure are not displayed for added clarity.

Similar articles

Cited by

References

    1. Clagett-Dame M, DeLuca HF. The role of vitamin A in mammalian reproduction and embryonic development. Annual review of nutrition. 2002;22:347–81. - PubMed
    1. Lotan R Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochimica et biophysica acta. 1980;605(1):33–91. - PubMed
    1. Maden M Retinoid signalling in the development of the central nervous system. Nature reviews Neuroscience. 2002;3(11):843–53. - PubMed
    1. McCaffery P, Drager UC. Regulation of retinoic acid signaling in the embryonic nervous system: a master differentiation factor. Cytokine & growth factor reviews. 2000;11(3):233–49. - PubMed
    1. Ross SA, McCaffery PJ, Drager UC, De Luca LM. Retinoids in embryonal development. Physiological reviews. 2000;80(3):1021–54. - PubMed

Publication types

MeSH terms

LinkOut - more resources